Abstracts Archive - Page 1015 of 2425 - ACR Meeting Abstracts

Abstract Number: 154 • 2018 ACR/ARHP Annual Meeting
Epigenetic Editing of FOXP3 in Human T Cells Is Sufficient to Induce Overexpression and Create a Regulatory T Cell Phenotype in Vitro
Christopher Dunn¹, Cassandra Velasco¹, Madison Andrews², Alexander Rivas³ and Matlock A. Jeffries⁴, ¹Rheumatology, Immunology, and Allergy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Arkansas for Medical Sciences, Little Rock, AR, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Defects in the number and function of naturally-occurring regulatory T cells (Tregs) have been identified in a variety of autoimmune diseases. The development of…
Abstract Number: 155 • 2018 ACR/ARHP Annual Meeting
Polyfunctional Synovial T-Cell Responses and Synovial Invasiveness Repressed By Blockade of Phosphodiesterase 4
Sarah M. Wade¹, Mary Canavan¹, Trudy McGarry¹, Siobhan C. Wade¹, Ronan Mullan², Douglas J. Veale³ and Ursula Fearon¹, ¹Molecular Rheumatology, School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, ²Department of Rheumatology,, Tallaght Hospital, Dublin, Ireland, ³Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland
Background/Purpose: Genetic and functional studies strongly support the role of T-cells in PsA pathophysiology. Effective targeting of T-cells requires a detailed understanding of their phenotypic…
Abstract Number: 156 • 2018 ACR/ARHP Annual Meeting
Assessing the Role of Ascvd Score in Primary Thrombosis Prophylaxis Strategy Among Asymptomatic Antiphospholipid Antibody Carriers
Yu Zuo¹, Akrithi Udupa², Jennifer Fan¹, Una E. Makris¹, David Karp^1,3 and Yu-min Shen¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ³Internal Medicine/Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Primary thrombosis prophylaxis among asymptomatic antiphospholipid antibody (aPL) carriers is challenging. The presence of aPL does not always lead to thromboembolic events. Additional factors…
Abstract Number: 157 • 2018 ACR/ARHP Annual Meeting
Identifying Additional Risk Factors Associated with Thrombosis and Pregnancy Morbidity in a Unique Cohort of Antiphospholipid Antibody Positive Chinese Patients
Yu Zuo¹, Chun Li², Song Zhang³, Una Makris¹, David Karp⁴ and Zhan-Guo Li⁵, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Peking University People's Hospital, Beijing, China, ³University of Texas Southwestern Medical Center, dallas, TX, ⁴Rheumatology, UT Southwestern Med Ctr, Dallas, TX, ⁵Rheum/Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: Risk stratification of asymptomatic aPL carriers is difficult. Our objective was to identify additional clinical and epidemiological predictors of arterial thrombosis, venous thrombosis, and…
Abstract Number: 158 • 2018 ACR/ARHP Annual Meeting
Incidence and Prevalence of Antiphospholipid Syndrome in a Health Management Organization (HMO): A 15-Year Study
Aurelia Luissi¹, Marina Scolnik² and Enrique R Soriano³, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina
Background/Purpose: Antiphospholipid Syndrome (APS) is an unusual disease and there are scarce epidemiological data. Our objective was to assess incidence and prevalence rates of APS…
Abstract Number: 159 • 2018 ACR/ARHP Annual Meeting
The Frequency of Screening and Prevalence of Antiphospholipid Antibodies in the General Population
Giordano Egiziano¹, Jessica Widdifield², Anisur Rahman³, Evelyne Vinet⁴, Cristiano S. Moura⁵, Jeffrey R. Curtis⁶ and Sasha Bernatsky⁷, ¹Department Medicine, McGill University, Montreal, QC, Canada, ²University Health Network, Toronto, ON, Canada, ³Rayne Institute, University College London, London, United Kingdom, ⁴Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁵The Centre for Outcomes Research and Evaluation (CORE), McGill University Health Centre, Montreal, QC, Canada, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: The antiphospholipid syndrome (APS) is defined by vascular thrombosis or pregnancy morbidity in the presence of persistently circulating antiphospholipid antibodies (aPL). Those positive for…
Abstract Number: 160 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Ecem Sevim¹, Danieli Andrade², Alessandra Banzato³, Maria Tektonidou⁴, Amaia Ugarte⁵, Cecilia B. Chighizola⁶, Lanlan Ji⁷, David Branch⁸, Guilherme Ramires de Jesus⁹, Laura Andreoli¹⁰, Michelle Petri¹¹, Ricard Cervera¹², Jason S. Knight¹³, Tatsuya Atsumi¹⁴ and Doruk Erkan¹⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ³Department of Cardiac Thoracic and Vascular Sciences, Clinical Cardiology, Thrombosis Centre, University of Padova, Padova, Italy, ⁴Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Athens University Medical School, Athens, Greece, ⁵Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Biscay, Spain, ⁶Rheumatology, Istituto Auxologico Italiano, University of Milan, Milan, Italy, ⁷Rheumatology and Immunology, Peking University First Hospital, Beijing, China., Beijing, China, ⁸Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, UT, ⁹Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁰Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ¹¹Johns Hopkins University School of Medicine, Baltimore, MD, ¹²Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ¹³., University of Michigan, Ann Arbor, MI, ¹⁴Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ¹⁵Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL) positive patients with or…
Abstract Number: 161 • 2018 ACR/ARHP Annual Meeting
Clinical and Laboratory Characteristics of Persistently Antiphospholipid Antibody Positive Patients: Retrospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Ecem Sevim¹, Diane F. Zisa², Danieli Andrade³, Vittorio Pengo⁴, Maria Tektonidou⁵, Amaia Ugarte⁶, Maria Gerosa⁷, Lanlan Ji⁸, Maria Efthymiou⁹, Guilherme Ramires de Jesus¹⁰, David Branch¹¹, Cecilia Nalli¹², Savino Sciascia¹³, H. Michael Belmont¹⁴, Paul R. Fortin¹⁵, Michelle Petri¹⁶, Esther Rodriguez-Almaraz¹⁷, Rosana Quintana¹⁸, Jason S Knight¹⁹, Rohan Willis²⁰, Tatsuya Atsumi²¹, Maria Laura Bertolaccini²², Doruk Erkan²³ and Medha Barbhaiya²⁴, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Department of Medicine, Weill Cornell Medicine, New York, NY, USA., New York, NY, ³Rheumatology, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ⁵Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Athens University Medical School, Athens, Greece, ⁶Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Biscay, Spain, ⁷Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, ⁸Rheumatology and Immunology, Peking University First Hospital, Beijing, China., Beijing, China, ⁹Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom, ¹⁰Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹¹Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, UT, ¹²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ¹³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ¹⁴Medicine, NYU Langone Health, New York, NY, ¹⁵Medicine, CHU de Québec - University of Laval, Quebec, QC, Canada, ¹⁶Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁸Argentina, GLADEL, Rosario, Argentina, ¹⁹University of Michigan, Ann Arbor, MI, ²⁰301 University Blvd, Antiphospholipid Standardization Laboratory, University of Texas Medical Branch, Galveston, TX, USA, Galveston, TX, ²¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²²King's College London, London, United Kingdom, ²³Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ²⁴Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: APS ACTION Registry was created to study long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic autoimmune diseases (SAIDx). The primary objective…
Abstract Number: 162 • 2018 ACR/ARHP Annual Meeting
Mammalian Target of Rapamycin (mTOR) Pathway Assessment in Antiphospholipid Antibody Positive Patients with Livedo Reticularis/racemosa
Ecem Sevim¹, Salma Siddique², Susan Chyou³, William D. Shipman³, Ines Eugenio-Fernandez⁴, Ariel Badger⁴, Orla O`Shea⁵, Stephane Zuily⁶, Joanna Harp⁷, Cynthia Magro⁸, Oral Alpan⁹, Theresa T. Lu¹⁰ and Doruk Erkan¹¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Pediatric Rheumatology, Nemours Children's Health System, Wilmington, DE, ³Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, ⁴O&O Alpan Medical Center, Fairfax, VA, ⁵Analytical Microscopy Core Laboratory, Hospital for Special Surgery, New York, NY, ⁶Université de Lorraine, CHRU Nancy, Nancy, France, ⁷Dermatology, Weill Cornell Medicine, New York, NY, ⁸Pathology, Weill Cornell Medicine, New York, NY, ⁹Allergy & Immunology, O&O Alpan Medical Center, Fairfax, VA, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Background/Purpose: Endothelial proliferation is a key finding in antiphospholipid antibody (aPL)-positive patients with microthrombosis. The mTOR pathway plays a role in the endothelial proliferation leading…
Abstract Number: 163 • 2018 ACR/ARHP Annual Meeting
Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase II Item Reduction Survey
Medha Barbhaiya¹, Stephane Zuily², Yasaman Ahmadzadeh³, Raymond P. Naden⁴, Karen Costenbader⁵ and Doruk Erkan⁶, ¹Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Université de Lorraine, CHRU Nancy, Nancy, France, ³Hospital for Special Surgery, New York, NY, ⁴New Zealand Ministry of Health, New Zealand Ministry of Health, Auckland, New Zealand, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Background/Purpose: An international multidisciplinary effort has been initiated to develop new rigorous, consensus-based criteria to identify patients with high likelihood of having APS. The methodological…
Abstract Number: 164 • 2018 ACR/ARHP Annual Meeting
Reliability of Lupus Anticoagulant and Anti-Phosphatidylserine/Prothrombin Autoantibodies in Antiphosphospholipid Syndrome: A Multicenter Study
Massimo Radin¹, Irene Cecchi², Elena Rubini³, Anna Scotta⁴, Roberta Rolla⁵, Barbara Montaruli⁶, Patrizia Pergolini⁵, Giulio Mengozzi⁴, Elena Muccini⁴, Antonella Vaccarino⁷, Dario Roccatello⁸ and Savino Sciascia⁹, ¹Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁴University of Turin, Turin, Italy, ⁵University of Turin, Novara, Italy, ⁶Ospedale Mauriziano, Turin, Italy, ⁷Ospedale S. Giovanni Bosco, Turin, Italy, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Correct interpretation of lupus anticoagulant (LA) tests is crucial for diagnosis of antiphospholipid syndrome (APS). However, testing patients during vitamin K antagonist (VKA) or…
Abstract Number: 165 • 2018 ACR/ARHP Annual Meeting
Clinical and Immunological Features of Antiphospholipid Syndrome in the Elderly: A Retrospective National Multicenter Study
Felix Grimaud¹, Cecile Yelnik², Marc Pineton de Chambrun³, Zahir Amoura³, Laurent Arnaud⁴, Nathalie Costedoat-Chalumeau⁵, Eric Hachulla², Marc Lambert², Melanie Roriz¹, Jean Sibilia⁴, Thomas Papo¹ and Karim Sacre⁶, ¹Université Paris-Diderot, Paris, France, ²Université de Lille, Lille, France, ³Université Pierre et Marie Curie, Paris, France, ⁴Université de Strasbourg, Strasbourg, France, ⁵Université Paris-Descartes, Paris, France, ⁶Bichat Hospital, Paris Diderot University, Paris, France
Background/Purpose: Antiphospholipid syndrome (APS) mainly affects women who are of child-bearing age. We aimed to describe the clinical and immunological features of APS patients diagnosed…
Abstract Number: 166 • 2018 ACR/ARHP Annual Meeting
Superior Sensitivity for Detection of Primary Antiphospholipid Syndrome By a 9-Test Panel in Patients with Deep Venous Thrombosis, Pulmonary Embolism, and Stroke or Transient Ischemic Attack
Konrad Dziamski¹, Katalin Banki² and Andras Perl³, ¹Rheumatology, SUNY Upstate Medical University, Syracuse, NY, ²Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY, ³Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by thrombotic events mediated by antiphospholipid antibodies (aPL). Most patients have primary APS (PAPS), while a significant minority has…
Abstract Number: 167 • 2018 ACR/ARHP Annual Meeting
Recurrent Thrombosis in Patients with Antiphospholipid Antibodies Following an Initial Venous or Arterial Thromboembolic Event
Tom Ortel¹, Sreelatha Meleth², Diane Catellier², Mark Crowther³, Doruk Erkan⁴, Paul R. Fortin⁵, David Garcia⁶, Nana Haywood², Steven R. Levine⁷, Michael J. Phillips² and Nedra Whitehead², ¹Duke University, Durham, NC, ²RTI International, Research, Triangle Park, NC, ³McMaster University, Hamilton, ON, Canada, ⁴Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ⁵Medicine, CHU de Québec - University of Laval, Quebec, QC, Canada, ⁶Hematology, University of Washington Medical Center, Seattle, WA, ⁷Neurology, State University of New York Downstate Medical Center, Brooklyn, NY
Background/Purpose: After an initial thromboembolic event (TE), several studies reported that patients with antiphospholipid syndrome (APS) manifest a high-risk for recurrent TE. A systematic review…
Abstract Number: 168 • 2018 ACR/ARHP Annual Meeting
IgG Anti-High-Density Lipoproteins Antibodies Discriminate between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients
Irene Cecchi¹, Massimo Radin², Elena Rubini³, Ana Suárez⁴, Dario Roccatello⁵, Savino Sciascia⁶ and Javier Rodríguez-Carrio⁷, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁴Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁷Bone and Mineral Research Unit, Instituto Reina Sofía de Investigación Nefrológica, REDinREN del ISCIII, Hospital Universitario Central de Asturias, Oviedo, Spain
Background/Purpose: Reliable biomarkers for risk stratification in Antiphospholipid Syndrome (APS) are still lacking. Anti-high-density lipoproteins antibodies (anti-HDL) showed promising results in predicting the development of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].